- IL-17 and IL-23 inhibitors lead for PASI 90
These biologics consistently outperformed other systemic therapies and represent the most reliable pathway to near-complete skin clearance in the short term. - Short-term rankings may underestimate IL-23 durability
Faster responses with IL-17 inhibitors contrast with more gradual but potentially more durable responses with IL-23 inhibitors, which may not be fully captured in 12- to 16-week analyses. - Safety profiles are broadly comparable in the short term
Serious adverse events were uncommon and did not differ meaningfully from placebo across systemic therapies. - Oral agents remain clinically relevant despite lower efficacy
Agents such as deucravacitinib and apremilast offer practical advantages and remain appropriate for patients who prefer oral therapy or are not candidates for biologics.
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
